HealthLynked (HLYK) AI Stock Analysis

• Market Cap: $4.44M
• Dividend Yield: N/A
• Average Volume (3M): 1.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: -28.51%
• EPS Growth: 38.80%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 2,866,104
• 10 Day Avg. Volume: 1,703
• 30 Day Avg. Volume: 1,730
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.93
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -1.72
• Enterprise Value/Market Cap: 2.61
• Enterprise Value/Revenue: 4.88
• Enterprise Value/Gross Profit: 4.99
• Enterprise Value/Ebitda: -5.53
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: $1.50 ▲(2.74% Upside)

HealthLynked's overall stock score is significantly impacted by its poor financial performance, characterized by declining revenues, high net losses, and negative equity. Technical analysis further indicates bearish momentum, and the valuation is unattractive due to negative earnings and no dividend yield. These factors collectively contribute to a low overall stock score.

Positive Factors

Business Model Strength

The diverse revenue streams from subscriptions and transaction fees provide a stable base for long-term growth, capitalizing on digital health trends.

Market Position

By improving patient engagement and healthcare delivery, HealthLynked positions itself well in the growing digital health market, fostering long-term demand.

Industry Trends

The increasing demand for digital health solutions supports HealthLynked's growth prospects, aligning with structural industry trends towards digitalization.

Negative Factors

Revenue Decline

Significant revenue contraction over recent years indicates challenges in maintaining market share and competitiveness, impacting long-term growth.

Negative Cash Flow

Persistent negative cash flow suggests operational inefficiencies and reliance on external financing, which may hinder sustainable growth.

Financial Instability

Negative equity highlights financial instability, posing risks to long-term viability and limiting the company's ability to invest in growth opportunities.

HealthLynked Business Overview & Revenue Model

Company Description

HealthLynked (HLYK) is a healthcare technology company focused on creating a patient-centric platform that enhances the delivery and management of healthcare services. The company operates primarily in the health information technology sector, providing a suite of solutions aimed at improving patient engagement, accessibility of health records, and facilitating communication between patients and healthcare providers. Core products include a network that enables patients to manage their medical history and connect with healthcare professionals, as well as tools for healthcare providers to streamline operations and improve patient care.

How the Company Makes Money

HealthLynked generates revenue through various channels, including subscription fees from healthcare providers who utilize its platform for managing patient data and communication. The company also earns money from transaction fees associated with services offered within its network, such as telehealth consultations and appointment scheduling. Additionally, partnerships with healthcare organizations and payers can lead to revenue-sharing arrangements that contribute to its earnings. By focusing on enhancing the efficiency of healthcare delivery and patient engagement, HealthLynked capitalizes on the growing demand for digital health solutions.

HealthLynked Financial Statement Overview

Summary

HealthLynked faces significant financial challenges, with declining revenues, high net losses, and negative equity. The company's reliance on external financing and persistent negative cash flows indicate financial distress. Urgent corrective measures are needed to stabilize the company's finances and improve its long-term viability.

Income Statement

The income statement shows declining revenues from $9,197,992 in 2021 to $3,008,361 in 2024, indicating significant revenue contraction. Gross profit margins remained relatively high, but the company experienced substantial net losses, increasing from -$1,012,203 in 2023 to -$6,131,479 in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges and negative earnings before interest and taxes.

Balance Sheet

The balance sheet reveals a negative stockholders' equity of -$3,129,209 in 2024, down from $804,730 in 2023, highlighting financial instability. The debt-to-equity ratio is effectively unmeasurable due to negative equity, suggesting high leverage. The equity ratio is negative, indicating liabilities exceed assets, signaling potential insolvency risks.

Cash Flow

Cash flow analysis shows consistently negative free cash flow, with -$3,494,122 in 2024. Operating cash flow is negative, indicating the company is not generating sufficient cash from operations to cover its expenses. There is a slight improvement in financing cash flow, suggesting reliance on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.37M	3.01M	5.72M	5.86M	9.20M	6.13M
Gross Profit	2.32M	2.91M	2.35M	5.40M	6.18M	4.97M
EBITDA	-2.10M	-4.36M	-2.75M	-7.05M	-9.85M	-4.73M
Net Income	-3.83M	-6.13M	-1.01M	-8.82M	-10.41M	-6.15M
Balance Sheet
Total Assets	1.76M	2.22M	4.28M	4.58M	10.69M	8.03M
Cash, Cash Equivalents and Short-Term Investments	10.91K	76.24K	247.22K	61.89K	3.29M	162.18K
Total Debt	6.08M	997.85K	1.97M	1.28M	978.19K	3.04M
Total Liabilities	7.20M	5.35M	3.48M	4.27M	3.49M	6.68M
Stockholders Equity	-5.43M	-3.13M	804.73K	314.45K	7.20M	1.35M
Cash Flow
Free Cash Flow	-1.59M	-3.50M	-4.15M	-4.39M	-3.79M	-2.14M
Operating Cash Flow	-1.59M	-3.49M	-4.14M	-4.36M	-3.77M	-2.12M
Investing Cash Flow	425.00K	422.40K	3.51M	-544.75K	-341.36K	1.81M
Financing Cash Flow	1.17M	2.90M	824.09K	1.68M	7.24M	356.80K

HealthLynked Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.46
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Positive. The current price of 1.46 is below the 20-day moving average (MA) of 1.46, below the 50-day MA of 1.50, and below the 200-day MA of 2.42, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 50.73 is Neutral, neither overbought nor oversold. The STOCH value of 60.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HLYK.

HealthLynked Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HealthLynked Corporate Events

HealthLynked Announces Reverse Stock Split Strategy

On September 4, 2025, HealthLynked Corp. announced a reverse stock split as part of its strategy to strengthen its capital structure and improve market positioning. This move aims to increase the per-share price without affecting shareholders’ ownership percentage, thereby enhancing visibility and attracting institutional investors. The company is also advancing its AI healthcare platform and telemedicine services, with ongoing discussions to integrate its technology with major insurance carriers, potentially driving significant recurring revenue and expanding its intellectual property portfolio.